Viking Therapeutics (VKTX)
The desk's stance
On our research list, not on the slate.
What the company does
The pure-play long shot: dual GLP-1/GIP agonist VK2735 advancing in Phase 3 subcutaneous trials (VANQUISH-1/2) with oral tablets entering Phase 3 in late 2026 — a ~$4B biotech betting its clean profile can carve out a lucrative slice from the duopoly.
In short: Metabolic and obesity drug developer. Category: Clinical Obesity Biotech Challenger. Sector: Healthcare, Biotechnology.
G-Street Value and Score
G-Street Value: $73.43, computed Oct 18, 2026 (confidence: low).
How we got there: 100% analyst leg $73.43 (2 analyst targets, credibility- and freshness-weighted, after 8% optimism discount). 3 analyst targets have no linked source and are shown but not counted.
G-Street Score: 31 out of 100 (Weak).
- Top-line growth & guidance: 10 of 32
- Margin power: 1 of 15
- Revenue visibility & quality: 5 of 11
- Profitability & balance sheet: 9 of 24
- Capital allocation & governance: 2 of 6
- Valuation, sentiment & momentum: 4 of 12
Our current thesis
Updated Oct 17, 2026
The thesis
- Dual GLP-1/GIP candidate VK2735 demonstrated 21.7% weight loss at 33 weeks without plateauing.
- Maintenance dosing schedules retain up to 97% weight loss, unlocking flexible chronic administration.
- Upsized secondary offerings provide critical liquidity runway to fund pivotal Phase 3 trials.
Risks
- Entrenched incumbents Eli Lilly and Novo Nordisk dominate global manufacturing and commercial scale.
- Zero revenue and accelerating cash burn (-$125M last quarter) create persistent dilution risk.
- Phase 3 clinical trial delays or safety events would catastrophically impair pipeline valuation.
What we're watching
- Third-quarter 2026 earnings release on October 28, 2026, updating clinical R&D cash burn.
- Initiation of Phase 3 oral VK2735 trials planned for fourth quarter 2026.
- Potential licensing or co-development partnership announcements with major pharmaceutical commercial leaders.
Latest
VKTX has slumped to $25.17, testing its 52-week low of $24.94, as post-offering equity dilution and accelerating clinical expenses overshadow recent maintenance data. The company remains pre-revenue with trailing twelve-month free cash burn expanding to -$418.4M ($125.2M burned in 2Q26), though fresh equity proceeds extend clinical runway. Market focus centers on the upcoming 3Q26 financial results on October 28, 2026, alongside fourth-quarter Phase 3 trial commencement milestones.
Key numbers
As of Oct 16, 2026: market cap $3.2B · gross margin 0.0% · net margin 0.0% · next earnings Oct 28, 2026.
Analyst price targets
Published analyst targets we could trace to a named source.
- Oppenheimer, Outperform: $120 target (October 2026). Source: fool.com
- Goldman Sachs, Neutral: $38 target (September 2026). Source: investing.com
On the Gainz Lab maps
Who it does business with
- Viking Therapeutics competes with Eli Lilly — The next pill & shot. VK2735's subcutaneous Phase 3 (VANQUISH) and oral formulations challenge Zepbound and Foundayo on tolerability and weight loss.